 "Biocon")
In a bid to expand its research base, India’s largest biopharmaceutical company Biocon has acquired some assets from Pfizer Healthcare to set up its second R&D plant in India.
The assets have been acquired by Biocon Biologics, a subsidiary of the Bengaluru-based company, for an undisclosed amount to set up a 60,000 square feet state-of-the-art R&D facility in Chennai.
“The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide,” said Christiane Hamacher, CEO, Biocon Biologics. The centre
